Seguir
Joseph P. Schacht
Joseph P. Schacht
Associate Professor of Psychiatry, University of Colorado School of Medicine
Dirección de correo verificada de cuanschutz.edu - Página principal
Título
Citado por
Citado por
Año
Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta‐analysis and systematic review
JP Schacht, RF Anton, H Myrick
Addiction biology 18 (1), 121-133, 2013
6062013
Marijuana craving in the brain
FM Filbey, JP Schacht, US Myers, RS Chavez, KE Hutchison
Proceedings of the National Academy of Sciences 106 (31), 13016-13021, 2009
2782009
Neural substrates of cue reactivity: association with treatment outcomes and relapse
KE Courtney, JP Schacht, K Hutchison, DJO Roche, LA Ray
Addiction biology 21 (1), 3-22, 2016
2332016
Marijuana withdrawal and craving: influence of the cannabinoid receptor 1 (CNR1) and fatty acid amide hydrolase (FAAH) genes
HM Haughey, E Marshall, JP Schacht, A Louis, KE Hutchison
Addiction 103 (10), 1678-1686, 2008
1712008
Associations between cannabinoid receptor-1 (CNR1) variation and hippocampus and amygdala volumes in heavy cannabis users
JP Schacht, KE Hutchison, FM Filbey
Neuropsychopharmacology 37 (11), 2368-2376, 2012
1522012
Individual and additive effects of the CNR1 and FAAH genes on brain response to marijuana cues
FM Filbey, JP Schacht, US Myers, RS Chavez, KE Hutchison
Neuropsychopharmacology 35 (4), 967-975, 2010
1472010
The incentive salience of alcohol: translating the effects of genetic variant in CNR1
KE Hutchison, H Haughey, M Niculescu, J Schacht, A Kaiser, J Stitzel, ...
Archives of general psychiatry 65 (7), 841-850, 2008
1162008
COMT val158met moderation of dopaminergic drug effects on cognitive function: a critical review
JP Schacht
The pharmacogenomics journal 16 (5), 430-438, 2016
1112016
Predictors of naltrexone response in a randomized trial: reward-related brain activation, OPRM1 genotype, and smoking status
JP Schacht, PK Randall, PK Latham, KE Voronin, SW Book, H Myrick, ...
Neuropsychopharmacology 42 (13), 2640-2653, 2017
1022017
Interacting effects of naltrexone and OPRM1 and DAT1 variation on the neural response to alcohol cues
JP Schacht, RF Anton, KE Voronin, PK Randall, X Li, S Henderson, ...
Neuropsychopharmacology 38 (3), 414-422, 2013
972013
Stability of fMRI striatal response to alcohol cues: a hierarchical linear modeling approach
JP Schacht, RF Anton, PK Randall, X Li, S Henderson, H Myrick
Neuroimage 56 (1), 61-68, 2011
872011
Intermediate cannabis dependence phenotypes and the FAAH C385A variant: an exploratory analysis
JP Schacht, RE Selling, KE Hutchison
Psychopharmacology 203, 511-517, 2009
812009
A methodological checklist for fMRI drug cue reactivity studies: development and expert consensus
H Ekhtiari, M Zare-Bidoky, A Sangchooli, AC Janes, MJ Kaufman, ...
Nature Protocols 17 (3), 567-595, 2022
612022
Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals
JP Schacht, RF Anton, PK Randall, X Li, S Henderson, H Myrick
Psychopharmacology 231, 3799-3807, 2014
532014
Investigating a novel fMRI cannabis cue reactivity task in youth
HC Karoly, JP Schacht, LR Meredith, J Jacobus, SF Tapert, KM Gray, ...
Addictive behaviors 89, 20-28, 2019
492019
Brain glutamate, GABA, and glutamine levels and associations with recent drinking in treatment‐naive individuals with alcohol use disorder versus light drinkers
JJ Prisciandaro, JP Schacht, AP Prescot, PF Renshaw, TR Brown, ...
Alcoholism: Clinical and Experimental Research 43 (2), 221-226, 2019
392019
Aripiprazole suppression of drinking in a clinical laboratory paradigm: influence of impulsivity and self‐control
RF Anton, JP Schacht, KE Voronin, PK Randall
Alcoholism: Clinical and Experimental Research 41 (7), 1370-1380, 2017
382017
Effects of a GABA-ergic medication combination and initial alcohol withdrawal severity on cue-elicited brain activation among treatment-seeking alcoholics
JP Schacht, RF Anton, PK Randall, X Li, S Henderson, H Myrick
Psychopharmacology 227, 627-637, 2013
382013
Systematic review and meta‐analysis of the moderating effect of rs1799971 in OPRM1, the mu‐opioid receptor gene, on response to naltrexone treatment of …
EE Hartwell, R Feinn, PE Morris, J Gelernter, J Krystal, AJ Arias, ...
Addiction 115 (8), 1426-1437, 2020
362020
GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders
L Leggio, CS Hendershot, M Farokhnia, A Fink-Jensen, MK Klausen, ...
Nature medicine 29 (12), 2993-2995, 2023
352023
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20